Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) promotes lung tumorigenesis via attenuating p53 stability
暂无分享,去创建一个
[1] L. Rimsza,et al. Neonatal expression of RNA-binding protein IGF2BP3 regulates the human fetal-adult megakaryocyte transition , 2017, The Journal of clinical investigation.
[2] H. Kirchner,et al. Investigating the prognostic value of KOC (K homology domain containing protein overexpressed in cancer) overexpression after curative intent resection of pancreatic ductal adenocarcinoma. , 2016, Journal of gastrointestinal oncology.
[3] N. Akimitsu,et al. Oncofetal protein IGF2BP3 facilitates the activity of proto-oncogene protein eIF4E through the destabilization of EIF4E-BP2 mRNA , 2016, Oncogene.
[4] H. Goel,et al. IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG , 2016, Oncogene.
[5] X. Chen,et al. The phosphatase DUSP2 controls the activity of the transcription activator STAT3 and regulates TH17 differentiation , 2015, Nature Immunology.
[6] Chan Gyu Lee,et al. Etoposide Induces Necrosis Through p53-Mediated Antiapoptosis in Human Kidney Proximal Tubule Cells. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.
[7] Jinjun Li,et al. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma , 2015 .
[8] Wei Wang,et al. TRAF Family Member-associated NF-κB Activator (TANK) Inhibits Genotoxic Nuclear Factor κB Activation by Facilitating Deubiquitinase USP10-dependent Deubiquitination of TRAF6 Ligase* , 2015, The Journal of Biological Chemistry.
[9] S. Jee,et al. IMP-3 promotes migration and invasion of melanoma cells by modulating the expression of HMGA2 and predicts poor prognosis in melanoma. , 2015, The Journal of investigative dermatology.
[10] Young-Joo Jang,et al. p53 activates G1 checkpoint following DNA damage by doxorubicin during transient mitotic arrest , 2014, Oncotarget.
[11] M. Lederer,et al. The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer. , 2014, Seminars in cancer biology.
[12] K. Taniuchi,et al. IGF2BP3-mediated translation in cell protrusions promotes cell invasiveness and metastasis of pancreatic cancer , 2014, Oncotarget.
[13] C. Chen,et al. Deubiquitination and stabilization of T-bet by USP10. , 2014, Biochemical and biophysical research communications.
[14] G. Pinna,et al. Post-transcriptional regulation of cyclins D1, D3 and G1 and proliferation of human cancer cells depend on IMP-3 nuclear localization , 2014, Oncogene.
[15] Jun Zhang,et al. IQGAP3 Promotes EGFR-ERK Signaling and the Growth and Metastasis of Lung Cancer Cells , 2014, PloS one.
[16] Weiwei Li,et al. IMP3 expression is associated with epithelial-mesenchymal transition in breast cancer. , 2014, International journal of clinical and experimental pathology.
[17] T. Hansen,et al. IMP3 RNP safe houses prevent miRNA-directed HMGA2 mRNA decay in cancer and development. , 2014, Cell reports.
[18] Yun Gao,et al. IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma , 2014, Journal of Cancer Research and Clinical Oncology.
[19] Jan Budczies,et al. Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer , 2013, PloS one.
[20] M. Fu,et al. USP10 inhibits genotoxic NF‐κB activation by MCPIP1‐facilitated deubiquitination of NEMO , 2013, The EMBO journal.
[21] P. Cui,et al. A KH-Domain RNA-Binding Protein Interacts with FIERY2/CTD Phosphatase-Like 1 and Splicing Factors and Is Important for Pre-mRNA Splicing in Arabidopsis , 2013, PLoS genetics.
[22] R. Trojanec,et al. Non-small cell lung cancer--genetic predictors. , 2013, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.
[23] Xiao-Jun Tian,et al. The Tumor-Suppressive Function of UNC5D and Its Repressed Expression in Renal Cell Carcinoma , 2013, Clinical Cancer Research.
[24] A. Mercurio,et al. IMP3 Protein Promotes Chemoresistance in Breast Cancer Cells by Regulating Breast Cancer Resistance Protein (ABCG2) Expression* , 2013, The Journal of Biological Chemistry.
[25] G. Wahl,et al. MDM2, MDMX and p53 in oncogenesis and cancer therapy , 2013, Nature Reviews Cancer.
[26] Wei Zhao,et al. An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer. , 2012, Cancer research.
[27] Reiko Nishihara,et al. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. , 2012, European journal of cancer.
[28] Stefan Hüttelmaier,et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? , 2012, Cellular and Molecular Life Sciences.
[29] A. Rosenwald,et al. Increased tumor cell proliferation in mantle cell lymphoma is associated with elevated insulin-like growth factor 2 mRNA-binding protein 3 expression , 2012, Modern Pathology.
[30] M. Dai,et al. Positive regulation of p53 stability and activity by the deubiquitinating enzyme Otubain 1 , 2012, The EMBO journal.
[31] Jennifer J Findeis-Hosey,et al. Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer , 2012, Biotechnic & histochemistry : official publication of the Biological Stain Commission.
[32] A. Mercurio,et al. Regulation of IMP3 by EGFR Signaling and Repression by ERβ: Implications for Triple Negative Breast Cancer , 2011, Oncogene.
[33] Y. Jeng,et al. Insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor formation and invasion and predicts poor prognosis in oral squamous cell carcinoma. , 2011, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[34] Jun Zhang,et al. Genetic and epigenetic control of UNC5C expression in human renal cell carcinoma. , 2011, European journal of cancer.
[35] K. Thennarasu,et al. Insulin Growth Factor-2 Binding Protein 3 (IGF2BP3) Is a Glioblastoma-specific Marker That Activates Phosphatidylinositol 3-Kinase/Mitogen-activated Protein Kinase (PI3K/MAPK) Pathways by Modulating IGF-2* , 2011, The Journal of Biological Chemistry.
[36] P. Cheung,et al. USP10 deubiquitylates the histone variant H2A.Z and both are required for androgen receptor-mediated gene activation , 2011, Nucleic acids research.
[37] Hao-dong Xu,et al. IMP3 expression is correlated with histologic grade of lung adenocarcinoma. , 2010, Human pathology.
[38] J. Cheville,et al. USP10 Regulates p53 Localization and Stability by Deubiquitinating p53 , 2010, Cell.
[39] N. Probst-Hensch,et al. IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. , 2009, Human pathology.
[40] D. Huntsman,et al. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype , 2009, Modern Pathology.
[41] Y. Jeng,et al. RNA‐binding protein insulin‐like growth factor II mRNA‐binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma , 2008, Hepatology.
[42] K. Rock,et al. Oncofetal protein IMP3 , 2008, Cancer.
[43] L. Regan,et al. Structure and function of KH domains , 2008, The FEBS journal.
[44] Zhong Jiang,et al. IMP3 Predicts Aggressive Superficial Urothelial Carcinoma of the Bladder , 2008, Clinical Cancer Research.
[45] K. Rock,et al. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations , 2007, Modern Pathology.
[46] P. Bourne,et al. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. , 2007, Human pathology.
[47] K. Rock,et al. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16INK4a expression , 2007, Modern Pathology.
[48] K. Rock,et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. , 2006, The Lancet. Oncology.
[49] A. Antsaklis,et al. CRD-BP/IMP1 Expression Characterizes Cord Blood CD34+ Stem Cells and Affects c-myc and IGF-II Expression in MCF-7 Cancer Cells* , 2005, Journal of Biological Chemistry.
[50] G. Brewer,et al. Targeted Knockdown of the RNA-binding Protein CRD-BP Promotes Cell Proliferation via an Insulin-like Growth Factor II-dependent Pathway in Human K562 Leukemia Cells* , 2004, Journal of Biological Chemistry.
[51] D. Ettinger,et al. Multidisciplinary management of lung cancer. , 2004, The New England journal of medicine.
[52] D. Ettinger,et al. NCCN: Non-small cell lung cancer. , 2001, Cancer control : journal of the Moffitt Cancer Center.
[53] F. Nielsen,et al. A Family of Insulin-Like Growth Factor II mRNA-Binding Proteins Represses Translation in Late Development , 1999, Molecular and Cellular Biology.
[54] S. Richard,et al. Self-association of the single-KH-domain family members Sam68, GRP33, GLD-1, and Qk1: role of the KH domain , 1997, Molecular and cellular biology.
[55] Liquid Biopsies. Non-small-cell lung cancer , 2015, Nature Reviews Disease Primers.
[56] A. Jemal,et al. Global Cancer Statistics , 2011 .
[57] M. Dai,et al. Positive regulation of p 53 stability and activity by the deubiquitinating enzyme , 2011 .
[58] A. Parwani. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16INK4a expression , 2008 .
[59] B. Yalcin,et al. Multidisciplinary management of lung cancer. , 2004, The New England journal of medicine.
[60] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.